TAUNS Laboratories, Inc.
TAUNS Laboratories, Inc. (197A.T) Stock Overview
Explore TAUNS Laboratories, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
55.2B
P/E Ratio
8.46
EPS (TTM)
$53.98
ROE
0.42%
197A.T Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of TAUNS Laboratories, Inc. (197A.T) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 62.46, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $776.17.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 8.46 and a market capitalization of 55.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
TAUNS Laboratories, Inc. develops and manufactures vitro diagnostic drugs & measuring instruments. It also provides import and export of industrial measuring instruments, medical, physical, chemical and measuring instruments. The company was founded in April 1987 and is headquartered in Izunokuni, Japan.
Masaki Nonaka
271
761-1 Kamishima, Izunokuni
2024